立体定向消融放疗对比标准放疗治疗1期非小细胞肺癌(TROG 09.02 CHISEL):一项3期、开放标签、随机对照试验
这项多中心3期随机对照试验在澳大利亚和新西兰的医院纳入101例不可手术或拒绝手术的周围型1期非小细胞肺癌患者,按2:1随机分配接受立体定向消融放疗(SABR)或标准放疗。SABR组局部治疗失败风险显著低于标准放疗组(HR 0.32,95%CI 0.13-0.77,p=0.0077),且未增加主要毒性。作者认为SABR应成为该患者群体的首选治疗。
要点
- SABR组局部治疗失败9/66(14%),标准放疗组11/35(31%),HR 0.32(95%CI 0.13-0.77,p=0.0077)。
- SABR组治疗相关4级不良事件1例(呼吸困难),3级7例;标准放疗组3级2例(胸痛)。
- 作者认为对于不可手术的周围型1期NSCLC,SABR应作为首选治疗。
核心结论
- 对于不可手术的周围型1期非小细胞肺癌患者,与标准放疗相比,SABR获得了更优的原发灶局部控制,且未增加主要毒性。
- 作者认为SABR应成为该患者群体的首选治疗。
研究设计与样本
- 多中心、3期、随机、对照试验,在澳大利亚11家医院和新西兰3家医院进行。
- 纳入年龄≥18岁、经活检确认的1期(T1-T2aN0M0)NSCLC(基于18F-氟脱氧葡萄糖PET诊断)、医学上不可手术或拒绝手术、ECOG体能状态评分0或1、肿瘤位于周围部位的患者。
- 按T分期和可手术性分层后以2:1比例随机分配至SABR组(n=66)或标准放疗组(n=35),采用最小化法随机,未预生成随机序列。
- SABR方案为54 Gy分3次每次18 Gy,或肿瘤距胸壁<2 cm时48 Gy分4次每次12 Gy;标准放疗方案为66 Gy分33次每日2 Gy或50 Gy分20次每日2.5 Gy,取决于机构偏好。
- 主要终点为局部治疗失败时间(依据RECIST 1.0评估),假设SABR较标准放疗有更优的局部控制;疗效分析基于意向性治疗,安全性分析基于符合方案集。
主要发现
- 2009年12月31日至2015年6月22日共入组101例患者,随机分配至SABR组(n=66)或标准放疗组(n=35)。
- SABR组5例(7.6%)、标准放疗组2例(6.5%)未接受治疗,每组另有4例在研究结束前退出。
- 截至数据截止日(2017年7月31日),标准放疗组局部治疗失败的中位随访时间为2.1年(IQR 1.2-3.6),SABR组为2.6年(IQR 1.6-3.6)。
- 101例中20例(20%)出现局部进展:SABR组9/66(14%),标准放疗组11/35(31%);SABR组局部治疗失败免除率优于标准放疗组(HR 0.32,95%CI 0.13-0.77,p=0.0077)。
- 两组均未达到局部治疗失败的中位时间;SABR组治疗相关4级不良事件1例(呼吸困难),3级不良事件7例(咳嗽2例、低氧1例、肺部感染1例、体重下降1例、呼吸困难1例、乏力1例),标准放疗组3级不良事件2例(胸痛)。
临床怎么用
- 作者认为,对于不可手术的周围型1期NSCLC患者,SABR应作为首选治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is widely used to treat inoperable stage 1 non-small-cell lung cancer (NSCLC), despite the absence of prospective evidence that this type of treatment improves local control or prolongs overall survival compared with standard radiotherapy. We aimed to compare the two treatment techniques. METHODS: We did this multicentre, phase 3, randomised, controlled trial in 11 hospitals in Australia and three hospitals in New Zealand. Patients were eligible if they were aged 18 years or older, had biopsy-confirmed stage 1 (T1-T2aN0M0) NSCLC diagnosed on the basis of 18F-fluorodeoxyglucose PET, and were medically inoperable or had refused surgery. Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1, and the tumour had to be peripherally located. Patients were randomly assigned after stratification for T stage and operability in a 2:1 ratio to SABR (54 Gy in three 18 Gy fractions, or 48 Gy in four 12 Gy fractions if the tumour was <2 cm from the chest wall) or standard radiotherapy (66 Gy in 33 daily 2 Gy fractions or 50 Gy in 20 daily 2·5 Gy fractions, depending on institutional preference) using minimisation, so no sequence was pre-generated. Clinicians, patients, and data managers had no previous knowledge of the treatment group to which patients would be assigned; however, the treatment assignment was subsequently open label (because of the nature of the interventions). The primary endpoint was time to local treatment failure (assessed according to Response Evaluation Criteria in Solid Tumors version 1.0), with the hypothesis that SABR would result in superior local control compared with standard radiotherapy. All efficacy analyses were based on the intention-to-treat analysis. Safety analyses were done on a per-protocol basis, according to treatment that the patients actually received. The trial is registered with ClinicalTrials.gov (NCT01014130) and the Australia and New Zealand Clinical Trials Registry (ACTRN12610000479000). The trial is closed to new participants. FINDINGS: Between Dec 31, 2009, and June 22, 2015, 101 eligible patients were enrolled and randomly assigned to receive SABR (n=66) or standard radiotherapy (n=35). Five (7·6%) patients in the SABR group and two (6·5%) in the standard radiotherapy group did not receive treatment, and a further four in each group withdrew before study end. As of data cutoff (July 31, 2017), median follow-up for local treatment failure was 2·1 years (IQR 1·2-3·6) for patients randomly assigned to standard radiotherapy and 2·6 years (IQR 1·6-3·6) for patients assigned to SABR. 20 (20%) of 101 patients had progressed locally: nine (14%) of 66 patients in the SABR group and 11 (31%) of 35 patients in the standard radiotherapy group, and freedom from local treatment failure was improved in the SABR group compared with the standard radiotherapy group (hazard ratio 0·32, 95% CI 0·13-0·77, p=0·0077). Median time to local treatment failure was not reached in either group. In patients treated with SABR, there was one grade 4 adverse event (dyspnoea) and seven grade 3 adverse events (two cough, one hypoxia, one lung infection, one weight loss, one dyspnoea, and one fatigue) related to treatment compared with two grade 3 events (chest pain) in the standard treatment group. INTERPRETATION: In patients with inoperable peripherally located stage 1 NSCLC, compared with standard radiotherapy, SABR resulted in superior local control of the primary disease without an increase in major toxicity. The findings of this trial suggest that SABR should be the treatment of choice for this patient group. FUNDING: The Radiation and Optometry Section of the Australian Government Department of Health with the assistance of Cancer Australia, and the Cancer Society of New Zealand and the Cancer Research Trust New Zealand (formerly Genesis Oncology Trust).
引用
- Ball D, Mai GT, Vinod S, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. 2019. PMID: 30770291. doi:10.1016/S1470-2045(18)30896-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。